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PRECLINICAL RESEARCH
ownregulated Expression of
lasminogen Activator Inhibitor-1
ugments Myocardial Neovascularization
nd Reduces Cardiomyocyte Apoptosis
fter Acute Myocardial Infarction
uosheng Xiang, PHD, Michael D. Schuster, MS, Tetsunori Seki, PHD, Piotr Witkowski, MD,
hawdee Eshghi, BS, Silviu Itescu, MD
ew York, New York
OBJECTIVES The aim of this study was to examine whether selective plasminogen activator inhibitor type
1 (PAI-1) downregulation in the acutely ischemic heart increases the myocardial microvas-
culature and improves cardiomyocyte (CM) survival.
BACKGROUND Endogenous myocardial neovascularization is an important process enabling cardiac func-
tional recovery after acute myocardial infarction. Expression of PAI-1, a potent inhibitor of
angiogenesis, is induced in ischemic heart tissue.
METHODS A sequence-specific catalytic deoxyribonucleic acid (DNA) enzyme was used to reduce PAI-1
levels in cultured endothelial cells and in ischemic myocardium. At the time of coronary artery
ligation, rats were randomized into three groups, each receiving an intramyocardial injection
(IMI) of a single dose at three different sites of the peri-infarct region consisting, respectively,
of DNA enzyme E2 targeting rat PAI-1 (E2), scrambled control DNA enzyme (E0), or
saline. Cardiomyocyte apoptosis, capillary density, and echocardiography were studied two
weeks following infarction.
RESULTS The E2 DNA enzyme, which efficiently inhibited rat PAI-1 expression in vitro, induced
prolonged suppression (2 weeks) of PAI-1 messenger ribonucleic acid and protein in rat
heart tissues after a single IMI. At two weeks, hearts from experimental rats had over five-fold
greater capillary density, 70% reduction in apoptotic CMs, and four-fold greater functional
recovery compared with controls.
CONCLUSIONS These results imply a causal relationship between elevated PAI-1 levels in ischemic hearts and
adverse outcomes, and they suggest that strategies to reduce cardiac PAI-1 activity may
augment neovascularization and improve functional recovery. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.047536–41) © 2005 by the American College of Cardiology Foundation
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slasminogen activator inhibitor type 1 (PAI-1) is the
rimary physiological regulator of both tissue-type and
rokinase plasminogen activators (1). In addition to increas-
ng coagulation and adversely affecting blood flow in large
aliber vessels, PAI-1 plays an important role in inhibiting
rowth of tissue microvasculature (2,3). This is believed to
e due to reduced plasmin-dependent matrix degradation
equired for angiogenesis and tissue neovascularization (4–
), direct pro-apoptotic effects on pre-formed endothelium
7), and reduced migration of endothelial progenitors by
nhibiting the binding of cell surface integrins regulating
ellular attachment and migration (8,9).
Despite frequent associations between elevated PAI-1
xpression and poor cardiovascular outcomes, a causal rela-
ionship has yet to be definitively established. Plasma levels
f PAI-1 are increased in patients with myocardial infarc-
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ew York. This study was partially funded by National Institutes of Health Grants
FA-HL-02-017 and RFA-AG-01-006.D
Manuscript received February 1, 2005; revised manuscript received March 30,
005, accepted April 13, 2005.ion, atherosclerosis, and restenosis (10–13). Moreover,
AI-1 messenger ribonucleic acid (mRNA) and protein
xpression are elevated in atherosclerotic human arteries and
ailed vein grafts (14–16), as well as in arterial walls and
eointima formation in various animal models of arterial
njury (17,18). Recently, urokinase-dependent plasminogen
ctivation and plasmin activity have been shown to be
equired for both efficient in vitro myogenesis and in vivo
keletal muscle regeneration (19,20). Together, these results
uggest there may be a direct causal link between the
egative effects of elevated PAI-1 levels on macrovascula-
ure and microvasculature, as well as on progenitor cell
igration and tissue repair.
The purpose of the present study was to examine whether
elective PAI-1 downregulation in the acutely ischemic
eart increases the myocardial microvasculature and im-
roves cardiomyocyte (CM) survival. The PAI-1 gene
xpression in heart tissue was targeted by a sequence-
pecific deoxyribonucleic acid (DNA) enzyme, a catalytic
NA molecule that can specifically cleave target mRNA at
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August 2, 2005:536–41 PAI-1 and Myocardial Neovascularizationhosphodiester bonds between unpaired purine and paired
yrimidine residues with similar efficacy to that of ri-
ozymes but with the stability of oligodeoxynucleotides
21,22). Our results strongly imply a causal relationship
etween elevated PAI-1 levels in ischemic hearts and
dverse outcomes, and they suggest that strategies to reduce
ardiac PAI-1 activity may augment neovascularization and
mprove functional recovery.
igure 1. Specificity of cleavage reaction for rat plasminogen activator inhib
cid (DNA) enzyme. (a) E2 cleaved the 24-base oligonucleotide S2, der
anner. (b) E2 also cleaved a rat PAI-1 mRNA transcript in a dose-depen
Abbreviation and Acronyms
AMI  acute myocardial infarction
CM  cardiomyocyte
DNA  deoxyribonucleic acid
EC  endothelial cell
E0  scrambled control deoxyribonucleic acid
enzyme E0
E2  deoxyribonucleic acid enzyme E2 targeting rat
plasminogen activator inhibitor type 1
IHC  immunohistochemical staining
IMI  intramyocardial injection
LAD  left anterior descending coronary artery
mRNA  messenger ribonucleic acid
PIR  peri-infarct region
PAI-1  plasminogen activator inhibitor type 1ontrol E0 nor E3 cleaved the rat PAI-1 mRNA transcript. (c) Single nucleo
revents cleavage of rat PAI-1 mRNA transcript by E3.ATERIALS AND METHODS
lease refer to Xiang et al. (23) for the DNA enzymes, in
itro cleavage, DNA enzyme stability in serum, cell trans-
ection, reverse transcription-polymerase chain reaction,
estern blots, PAI-1 activity assay, measurement of myo-
yte apoptosis, quantitation of capillary density, and analyses
f myocardial function regarding the methodology in the
revious text.
n vitro transcription. Rat PAI-1 cDNA was amplified
sing RT-PCR from total RNA of cultured rat aortic
ndothelial cells (ECs) (gift from Dr. G. Ceballos-Reyes,
nstituto Politecnico Nacional de Mexico D.F.). Primer pair
sed was 5=AGC ACA CAG CCA ACC ACA GCT3=
forward primer) and 5=CTT CGA GAG TCT GAG
TC TG3= (reverse primer) (Genbank accession no.
24067, position 48-1499). For other steps, follow Xiang
t al. (23).
nimals, surgical procedures and injection of DNA
nzyme. Rowett (rnu/rnu) athymic nude rats (Harlan
prague Dawley, Indianapolis, Indiana) were used in studies
pproved by the Columbia University Institute for Animal
are and Use Committee. After anesthesia, a left thoracot-
my was performed, the pericardium was opened, and the
pe 1 (PAI-1) messenger ribonucleic acid (mRNA) by E2 deoxyribonucleic
rom the sequence of rat PAI-1 mRNA, in a dose- and time-dependent
anner to give the 156 nucleotide cleavage product. Neither the scrambleditor ty
ived f
dent mtide substitution between rat and human PAI-1 mRNA target sequence
l
A
g
s
(
i
(

s
s
t
s
s
I
f
Z
t

i
g
c
fi
S
C
d
R
S
e
E
t
m
a
o
T
f
t
P
g
c
n
t
P
F
a
o
E
i
t
538 Xiang et al. JACC Vol. 46, No. 3, 2005
PAI-1 and Myocardial Neovascularization August 2, 2005:536–41eft anterior descending coronary artery (LAD) was ligated.
t the time of surgery, animals were randomized into three
roups, each receiving intramyocardial injection (IMI) of a
ingle dose at three different sites of the peri-infarct region
PIR) consisting, respectively, of DNA enzyme E2 target-
ng rat PAI-1 (E2), scrambled control DNA enzyme E0
E0), or saline. A 100-l injection of solution included 30
l DNA enzyme (300 g), 20 l Superfect, and 50 l
aline. Each group consisted of 6 to 10 rats. Animals were
acrificed at two weeks for various studies (see the following
ext). An additional group of saline-treated controls was
acrificed at 48 h for immunohistochemical staining (IHC)
tudies.
mmunohistochemistry. The IHC staining was per-
ormed using the Histostain-SP kit (catalogue no. 95-9551,
ymed Laboratories, California) according to the manufac-
urer’s recommendations. The slides were incubated with 10
g/ml of polyclonal rabbit anti-rat PAI-1 antibody (Amer-
can Diagnostics, Greenwich, Connecticut) containing 0.1%
oat serum for 1 h at 37°C. The PAI-1 positively staining
ells are visualized as brown and counted in a minimum of
ve low-power fields (100).
igure 2. Deoxyribonucleic acid (DNA) enzymes inhibit induction of end
cid (mRNA) and protein, and demonstrate serum resistance. (a) Results of
f rat endothelial cells (ECs) with E2 results in significant inhibition of tra
0 (p  0.01, n  4). (b) Results of Western blot using PAI-1 specific an
nhibition of TGF-beta induced expression of PAI-1 protein, relative to the E
hymidine at the 3= end demonstrates resistance to degradation in medium withtatistical analysis. Data are presented as mean  SEM.
omparisons between two groups were made by the Stu-
ent’s t test. Values of p  0.05 were considered significant.
ESULTS
pecific cleavage of rat PAI-1 mRNA by E2 DNA
nzyme. We designed two DNA enzymes, termed E2 and
3, to target specific pyrimidine-purine junctions at or near
he translational start site AUG of rat and human PAI-1
essenger RNA, a region that is conserved between species
nd has low relative free energy. Evidence for the specificity
f the DNA enzymatic reactions can be seen in Figure 1.
he E2 cleaved the 24-base oligonucleotide S2, synthesized
rom the sequence of rat PAI-1 mRNA, in a dose- and
ime-dependent manner (Fig. 1a). The E2 also cleaved a rat
AI-1 transcript in a dose-dependent manner by 2 to 4 h to
ive the 156 nucleotide cleavage product (Fig. 1b). In
ontrast, neither the scrambled control DNA enzyme E0
or E3 cleaved the rat PAI-1 transcript. Since the rat PAI-1
ranscript differs by only one nucleotide from the human
AI-1 transcript, which can be cleaved by E3 (Fig. 1c),
us plasminogen activator inhibitor type 1 (PAI-1) messenger ribonucleic
se transcription-polymerase chain reaction demonstrating that transfection
ming growth factor-beta–induced expression of PAI-1 mRNA, relative to
, demonstrating that transfection of rat ECs with E2 results in significant
32ogeno
rever
nsfor
tisera0 (p  0.01, n  3). (c) P-labeled PAI-1 DNA enzyme with inverted
2%, but not 20%, serum (representative of two separate experiments).
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August 2, 2005:536–41 PAI-1 and Myocardial Neovascularizationhese results demonstrate the exquisite target specificity of
hese DNA enzymes.
NA enzymes inhibit induction of endogenous PAI-1
RNA and protein. To determine the effect of DNA
nzymes on endogenous PAI-1 production, rat ECs were
rown to subconfluence and transfected with E2 or E0.
ransfected cells were then activated with transforming
rowth factor (TGF)-beta for 8 h to induce maximal
xpression of PAI-1. Densitometric analysis of polymerase
hain reaction products following reverse transcription of
ellular mRNA showed that E2 inhibited the induction of
AI-1 mRNA by TGF-beta in cultured rat ECs by 52%,
elative to E0 (1.62  0.10 for E0 vs. 0.85  0.03 for E2;
 0.01) (Fig. 2a). Similar inhibition of TGF-beta–
nduced PAI-1 protein expression was observed following
ransfection of ECs with E2, but not E0 (0.37  0.05 for
0 vs. 0.26  0.06 for E2; p  0.05) (Fig. 2b). Further
xperiments indicate that an inverted thymidine at the 3=
nd can protect the PAI-1 DNA enzyme against nucleolytic
egradation at physiologic serum concentrations likely to be
ncountered in vivo (Fig. 2c), enabling inhibition of cellular
AI-1 activity by 25%. Additionally, we also used two
uman DNA enzymes E1 and E3 targeting human PAI-1
RNA to transfect human umbilical vein ECs and observed
igure 3. Effects of intramyocardial plasminogen activator inhibitor type 1
essenger ribonucleic acid (mRNA) and protein expression. (a) Results of r
escending coronary artery (LAD) ligation and direct injection of DNA
RNA expression after E2 injection relative to E0 (p  0.01, n  6 to 10
nd rat PIR 48 h after LAD ligation. (Left) The PAI-1 expression in rat
tained cells were visualized as brown with immunoperoxidase technique an
nalyses showing reduced numbers of PAI-1 expressing cells at the PIR afte
weeks after LAD ligation and direct injection of E2 at the PIR, showing red
elative to saline (p  0.01, n  6 to 10).arked reduction of cellular human PAI-1 activity (6.43 
.29 U/ml for E1 or 5.58  1.33 U/ml for E3 vs. 8.09 
.19 U/ml for E0; p  0.01).
MI of E2 at the time of acute myocardial infarction
AMI) reduces early PAI-1 mRNA and protein expres-
ion in the ischemic heart. Next, we investigated the in
ivo biological activities of the PAI-1 DNA enzyme in a rat
odel of AMI. As shown in Figure 3a, at 48 h after LAD
igation and induction of AMI in rats, direct IMI of E2 at
he PIR at the time of LAD ligation resulted in significantly
educed PAI-1 mRNA levels in the rat heart left ventricle,
s measured by RT-PCR (0.86 0.12 vs. 0.35 0.11; p
.01). The IHC studies in consecutive sections showed that
AI-1 protein expression was dramatically increased in rat
Ms at the PIR, but not at sites distal to the infarct zone in
nimals treated with E0 (Fig. 3b, left panel). Increased
AI-1 expressions are also observed in some ECs at the PIR
data not shown). In contrast, animals treated with E2 did
ot show such an increase in PAI-1 expression at 48 h.
oreover, as shown in Figure 3b, right panel, at 48 h, there
as a 2.5-fold reduction in the number of PAI-1 positive
ells at the PIR of E2-treated animals than E0-treated
ontrols (67.2  13.3/low-power field for E0 vs. 26.6 
.4/low- power field for E2; p  0.01).
-1) deoxyribonucleic acid (DNA) enzyme injection on myocardial PAI-1
transcription-polymerase chain reaction (RT-PCR) 48 h after left anterior
es at the peri-infarct region (PIR), showing reduced myocardial PAI-1
Immunohistochemical staining (IHC) analysis of normal rat myocardium
omyocytes of animals treated with E0, but not with E2. PAI-1 positively
-diaminobenzidine tetrahydrochloride substrate. (Right) quantitative IHC
injection relative to E0 (p 0.01, n 6 to 10). (c) The RT-PCR analyses(PAI
everse
enzym
). (b)
cardi
d 3,3=
r E2uced level of PAI-1 mRNA in infarcted left ventricles after E2 injection
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PAI-1 and Myocardial Neovascularization August 2, 2005:536–41MI of E2 results in prolonged suppression of PAI-1
RNA and enhanced myocardial neovascularization.
e then investigated whether a single IMI of E2 at the
ime of AMI resulted in short-term or prolonged down-
egulation of myocardial PAI-1 mRNA expression. Two
eeks after LAD ligation, myocardium from saline-treated
nimals demonstrated two-fold higher levels of PAI-1
RNA than sham operated rats after normalization for
lyceraldehyde-3-phosphate dehydrogenase control (1.96
.32 vs. 1.00  0.05; p  0.01) (Fig. 3c). Animals who
eceived E2 at the time of infarction continued to demon-
trate reduced myocardial PAI-1 mRNA at two weeks, with
ean levels being 60% lower than in LAD-ligated controls
1.33  0.25 vs. 1.96  0.32; p  0.01) (Fig. 3c). Because
hese results indicated a surprisingly prolonged effect of the
arly, single-dose administration of the DNA enzyme, we
ext examined whether prolonged PAI-1 downregulation
nfluenced myocardial neovascularization after AMI. His-
ologic examination revealed that a single injection with E2
t the time of infarction was followed at two weeks by a
ignificant increase in infarct zone microvascularity, cellu-
arity, and numbers of factor VIII-positive capillaries, and
y reduction in matrix deposition and fibrosis in comparison
o controls. Hearts from animals injected with E2 had
ve-fold greater capillary density at the PIR compared with
igure 4. Effects of intramyocardial plasminogen activator inhibitor typ
eovascularization, cardiomyocyte (CM) apoptosis, and functional recovery
eovascularization at the peri-infarct region (PIR) 2 weeks later in compar
essels lacking smooth muscle layers and positively staining for CD31. (b
esulted in 70% reduction in CM apoptosis at the PIR 2 weeks later compar
UNEL staining (blue) and troponin I staining (brown). This was not obs
mprovement in left ventricular ejection fraction 2 weeks later in comparison toearts injected with E0 (13.3  2.5 for E2 vs. 2.5  1.4 for
0; p  0.01) (Fig. 4a). No increase in capillary numbers
as observed at sites distal to the infarct zone.
yocardial PAI-1 downregulation reduces CM apopto-
is and improves functional cardiac recovery after AMI.
inally, we sought to determine the effects of myocardial
AI-1 downregulation on CM apoptosis and functional
ardiac recovery after AMI. By concomitant staining for the
M-specific marker troponin I and DNA end-labeling,
0% lower numbers of apoptotic CMs were detected in
nfarcted left ventricles of rats injected with E2 compared
ith controls receiving E0 (18.0  2.5 for E0 vs. 5.6  1.1
or E2; p  0.01) (Fig. 4b). These differences were
articularly evident within the peri-infarct rim, where the
mall, irregularly shaped CM in the controls treated with
ither saline or E0 had the highest index of apoptotic nuclei.
y two-dimensional echocardiography, rats receiving E2
emonstrated a nearly four-fold greater recovery in global
ardiac function at two weeks than animals receiving E0
mean left ventricular ejection fraction recovery 11 2% vs.
 1%; p 0.01) (Fig. 4c). Together, these results indicate
hat downregulation of PAI-1 by E2 enhanced peri-infarct
eovascularization, increased CM survival, and thereby
mproved myocardial function.
PAI-1) deoxyribonucleic acid (DNA) enzyme injection on myocardial
acute myocardial infarction. (a) E2 injection induced significantly greater
o E0 (p  0.01, n  6 to 10). Capillaries are characterized as small lumen
injection at the time of left anterior descending coronary artery ligation
th infarct controls (p 0.01, n 6 to 10), as determined by concomitantlye 1 (
after
ison t
) E2
ed wierved with E0 injection. (c) E2 injection induced significantly greater
E0 (p  0.01, n  6 to 10), as measured by echocardiographic studies.
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August 2, 2005:536–41 PAI-1 and Myocardial NeovascularizationISCUSSION
ndogenous myocardial neovascularization is an important
rocess enabling cardiac functional recovery after AMI
24,25). Approaches that enhance myocardial neovascular-
zation after acute ischemia, such as bone marrow mobili-
ation and/or direct injection of endothelial progenitor cells,
esult in protection of “at-risk” CMs at the PIR against
poptosis and prevention of adverse remodeling (26). In this
tudy, expression of PAI-1 markedly increased in the border
one of the infarct compared with sites distal to the infarct
one, and such an elevation may be affected more signifi-
antly by PAI-1 DNA enzymes, therefore leading to more
bvious effects. Because targeted inhibition of PAI-1 ex-
ression in cardiac tissue including CMs and ECs was
ssociated with enhanced myocardial neovascularization and
educed CM apoptosis, our data suggest that the complex
ffects of PAI-1 on CMs and vascular endothelium directly
esult in reduced viability and survival of CMs in vivo.
urthermore, our results strongly imply a direct causal
elationship between elevated serum/tissue PAI-1 levels and
dverse cardiovascular outcomes, including myocardial in-
arction, atherosclerosis, and restenosis (13–16).
To develop an approach to inhibit PAI-1 expression that
ight have clinical applicability, we focused on the use of a
ew generation of catalytic nucleic acids containing DNA
olecules with catalytic activity for specific RNA sequences
21,22). These DNA enzymes exhibit greater catalytic
fficiency than hammerhead ribozymes, offer greater sub-
trate specificity, are more resistant to chemical and enzy-
atic degradation, and are far cheaper to synthesize.
Together, our results indicate that inhibition of cardiac
AI-1 mRNA by a sequence-specific catalytic DNA en-
yme is a feasible approach for enhancing cardiac neovas-
ularization after AMI. More importantly, our data dem-
nstrate the general concept that strategies to reduce cardiac
AI-1 activity may result in protection against CM apo-
tosis and in improved functional recovery after acute
schemia.
eprint requests and correspondence: Dr. Guosheng Xiang,
olumbia-Presbyterian Medical Center, 630 West 168th Street,
&S 14-402, New York, New York 10032. E-mail: gx15@
olumbia.edu.
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